FTC approves Amneal’s $1.45bn acquisition of Impax

The US Federal Trade Commission (FTC) has issued a final approval of Amneal’s $1.45 billion acquisition of Impax.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

FTC hits Amneal, Impax and Endo with antitrust suit

28 January 2021 The US Federal Trade Commission is suing Endo Pharmaceuticals, Impax Laboratories, and Impax’s owner Amneal Pharmaceuticals, alleging that they were party to a 2017 agreement that violated antitrust law.

Americas

Impax to divest 10 products amid acquisition by Amneal

30 April 2018 The Federal Trade Commission is requiring Impax to divest rights and assets for ten products, as part of a settlement resolving charges that Amneal’s $1.45 billion acquisition would be anti-competitive.

Americas

Amneal and Impax merge to become ‘fifth largest’ generics company

19 October 2017 Amneal Pharmaceuticals and Impax Laboratories have agreed to merge, in a deal the companies say will create the fifth largest generics drugs business in the US.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

FTC approves Amneal’s $1.45bn acquisition of Impax

More on this story

Editor's picks

Editor's picks

More features